Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer

摘要: The aim of this prospective study was to evaluate the value (18)F-FDG PET for assessment chemotherapy response in patients with non-small cell lung cancer. Furthermore, part objective compare 2 methods quantify changes glucose metabolism. METHODS: In 51 patients, dynamic performed before and at 5-8 wk into treatment. Simplified measure metabolism (standardized uptake [SUV]) quantitative measures (metabolic rate [MR(Glu)]), derived from Patlak analysis, were evaluated. overall survival progression-free respect MR(Glu) SUV calculated using Kaplan-Meier estimates. Fractional tumor use stratified by median also predefined EORTC (European Organization Research Treatment Cancer) metabolic criteria, criteria applying cutoff levels similar those RECIST (Response Evaluation Criteria Solid Tumors) RESULTS: When stratifying DeltaMR(Glu) DeltaSUV, difference (P = 0.017 DeltaMR(Glu), P 0.018 DeltaSUV) 0.002 0.0009 highly significant. response, as used size measurement (RECIST) showed significant differences DeltaSUV between categories 0.0003) well 0.027). CONCLUSION: degree chemotherapy-induced determined is predictive patient outcome, groups widely differing probabilities. therapy monitoring seems clinically feasible, because simplified (SUV) are sufficiently reliable can replace more complex, (MR(Glu)) population.